Valerie Pracilio Csik

Valerie Pracilio Csik

Auto-generated profile, based on publicly available information

Valerie Pracilio Csik

Sidney Kimmel Cancer Center Jefferson Health , Philadelphia, PA 19107

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in JCO Oncology Practice
Verified
Journal Article
Open access
NHNathan R. Handley
Nathan R. Handley
AHArianna Heyer
Arianna Heyer
RGRachel E. Granberg
Rachel E. Granberg
ABAdam F. Binder
Adam F. Binder
AGAlexzandra T. Gentsch
Alexzandra T. Gentsch
KRKristin L. Rising
Kristin L. Rising
PURPOSE: The COVID-19 pandemic necessitated a rapid expansion of telehealth use in oncology, a specialty in which prior utilization was low in part because of barriers perceived by providers. Understanding the changing perceptions of medical oncology providers during the pandemic is critical for continued expansion and improvement of telehealth in cancer care. This study was designed to identify medical oncology providers' perceptions of telehealth video visits as influenced by the COVID-19 pandemic. METHODS: We conducted semi-structured interviews with medical oncology providers from November 20, 2020, to January 27, 2021, at the Sidney Kimmel Cancer Center at Thomas Jefferson University, a National Cancer Institute–designated cancer center in an urban, academic health system in Philadelphia, PA. We assessed provider perceptions of the impact of the COVID-19 pandemic on (1) provider-level comfort and willingness for telehealth, (2) provider-perceived patient comfort and willingness to engage in telehealth, and (3) continued barriers to successful telehealth use. RESULTS: Volunteer and convenience sampling resulted in the participation of 25 medical oncology providers, including 18 physicians and seven advanced practice providers, in semi-structured interviews. Of the 25 participants, 13 (52%) were female and 19 (76%) were White, with an average age of 48.5 years (standard deviation = 12.6). Respondents largely stated an increased comfort level and willingness for use of video visits. In addition, respondents perceived a positive change in patient comfort and willingness, mostly driven by convenience, accessibility, and reduced risk of COVID-19 exposure. However, several reported technologic issues and limited physical examination capability as remaining barriers to telehealth adoption. CONCLUSION: The rapid adoption of telehealth necessitated by the COVID-19 pandemic has increased provider-level and provider-perceived patient comfort and willingness to engage in video visits for cancer care. As both providers and patients increasingly accept telehealth across many use cases, future work should focus on further addressing technology and physical examination barriers and ensuring continued reimbursement for telehealth as a routine part of covered care.

1 January 2021 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
VCValerie P. Csik
Valerie P. Csik
MLMichael Li
Michael Li
ABAdam F. Binder
Adam F. Binder
NHNathan R. Handley
Nathan R. Handley
PURPOSE Acute care utilization (ACU), including emergency department (ED) visits or hospital admissions, is common in patients with cancer and may be preventable. The Center for Medicare & Medicaid Services recently implemented OP-35, a measure in the Hospital Outpatient Quality Reporting Program focused on ED visits and inpatient admissions for 10 potentially preventable conditions that arise within 30 days of chemotherapy. This new measure exemplifies a growing focus on preventing unnecessary ACU. However, identifying patients at high risk of ACU remains a challenge. We developed a real-time clinical prediction model using a discrete point allocation system to assess risk for ACU in patients with active cancer. METHODS We performed a retrospective cohort analysis of patients with active cancer from a large urban academic medical center. The primary outcome, ACU, was evaluated using a multivariate logistic regression model with backward variable selection. We used estimates from the multivariate logistic model to construct a risk index using a discrete point allocation system. RESULTS Eight thousand two hundred forty-six patients were included in the analysis. ED utilization in the last 90 days, history of chronic obstructive pulmonary disease, congestive heart failure or renal failure, and low hemoglobin and low neutrophil count significantly increased risk for ACU. The model produced an overall C-statistic of 0.726. Patients defined as high risk (achieving a score of 2 or higher on the risk index) represented 10% of total patients and 46% of ACU. CONCLUSION We developed an oncology acute care risk prediction model using a risk index-based scoring system, the REDUCE (Reducing ED Utilization in the Cancer Experience) score. Further efforts to evaluate the effectiveness of our model in predicting ACU are ongoing. (C) 2021 by American Society of Clinical Oncology

1 November 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
RTRyan B. Thomas
Ryan B. Thomas
VMVittorio Maio
Vittorio Maio
ACAnna Chen
Anna Chen
SPSeojin Park
Seojin Park
DWDexter Waters
Dexter Waters
VCValerie P. Csik
Valerie P. Csik
PURPOSE:To explore mean difference between Oncology Care Model (OCM) total costs and target price among breast cancer episodes by stage under the Centers for Medicare and Medicaid Services OCM paym...

14 August 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
SBSibel Blau
Sibel Blau
VCValerie Csik
Valerie Csik
ETEric Tetzlaff
Eric Tetzlaff
TPTodd Pickard
Todd Pickard
JMJennifer A Marks
Jennifer A Marks
SGStephen Grubbs
Stephen Grubbs
The global burden of cancer is significant, with millions of new diagnoses expected annually, necessitating highly coordinated and patient-centered care. To address workforce shortages, increasing case complexity, and high rates of clinician burnout, ASCO advocates for a transition from traditional physician-centric models to interdependent, multidisciplinary team-based care. This paper outlines the essential characteristics of high-functioning oncology teams, which include clearly defined roles and responsibilities, established leadership, effective communication, shared goals, accountability, and a culture of psychological safety. To optimize team workflows, visual tools such as swim lane diagrams are recommended to clearly delineate tasks across various professionals, including oncologists, advanced practice providers, nurses, pharmacists, and support staff, thereby preventing redundancy and improving efficiency. Successfully implementing optimal care teams directly contributes to practice health by fostering supportive environments that enhance job satisfaction, improve clinician retention, and mitigate burnout, which currently affects over half of the oncology workforce. However, significant systemic barriers hinder the optimization of these collaborative models. Challenges include declining reimbursement rates, burdensome utilization management policies such as prior authorizations, and a lack of organizational support for nonbillable collaborative time. Furthermore, the rapid integration of artificial intelligence introduces new complexities to team dynamics and workflows. Ultimately, sustaining optimal team-based oncology care requires ongoing re-evaluation of roles and strong partnerships between clinical and administrative leaders to ensure long-term practice health and improved patient experiences.

10 January 2025 in American Journal of Medical Quality
Verified
Journal Article
Closed access
CAChelsey R. Ali
Chelsey R. Ali
ALAlexander M. PharmD Litvintchouk
Alexander M. PharmD Litvintchouk
PMPatrick Moeller
Patrick Moeller
RDRaegan Ma Davis
Raegan Ma Davis
EHEmma Mha Hannan
Emma Mha Hannan
VCValerie P. Mph Csik
Valerie P. Mph Csik
This retrospective study aimed to describe the characteristics of cancer patients undergoing depression and distress screening at the Sidney Kimmel Cancer Center and to assess factors associated with their screening results. Data were retrieved from electronic medical records of adult Sidney Kimmel Cancer Center patients with at least one oncology encounter between January 2021 and June 2022, who underwent both depression and distress screening using the Patient Health Questionnaire-2/9 for depression and the National Comprehensive Cancer Network distress thermometer for distress during the encounter. Demographics, clinical factors, and screening results were analyzed using descriptive statistics and binary logistic regression. A total of 1954 cancer patients were screened for psychological needs. Of these, 110 (5.6%) screened positive for depression and 830 (42.5%) screened positive for distress. About 69.1% of patients who screened positive for depression also screened positive for distress. Conversely, 9.2% of patients who screened positive for distress also screened positive for depression. Cancer patients >65 years old were found significantly less likely to screen positive for both distress and depression, while males were found significantly less likely to screen positive for distress. African American patients were found to be significantly more likely than White patients to screen positive for both distress and depression (odds ratio: 2.58; confidence interval: 1:53–4.34). In this study, a higher proportion of cancer patients were found to be distressed than depressed, suggesting that the National Comprehensive Cancer Network distress thermometer may be a more useful tool in identifying psychosocial concerns in this population. Differences in depression and distress scores were significantly associated with age, sex, and race. These findings highlight the need for the implementation of effective screening strategies to better address the psychosocial needs of cancer patients. Further research is warranted to validate these findings and assess the impact of distress screening on patient outcomes across various oncology settings.

22 January 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
MCMaureen E Canavan
Maureen E Canavan
SWSarah Westvold
Sarah Westvold
VCValerie Csik
Valerie Csik
JFJeffrey Franks
Jeffrey Franks
GRGabrielle Rocque
Gabrielle Rocque
KAKerin B Adelson
Kerin B Adelson
It has long been assumed that academic oncology practices are disadvantaged in value-based payment programs because of patient complexity and research costs. This assumption has not been tested. The Oncology Care Model (OCM) was a Medicare alternative payment model, which sought to curb costs while improving care. We assessed the impact of clinical trial participation on 2 outcomes: (1) cost and (2) practice performance among 3 participating National Cancer Institute–designated cancer centers using a random effects meta-analysis. The mean total Medicare cost per episode was $42 225 for clinical trial episodes and $34 937 for nonclinical trial episodes. Despite higher total costs, clinical trial episodes were more likely to be under spending targets than non–clinical trial episodes (odds ratio = 0.37, 95% confidence interval = 0.25 to 0.48). Drug costs in clinical trial episodes were lower than in nonclinical trial episodes, although this was only statistically significant at the largest volume practice. In conclusion, clinical trials may offer an advantage in value-based programs.